Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 352

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 352
---
4, the Company recorded stock-based compensation expense of $1.9 million, of which $1.0 million was related to research
and development and $0.9 million was related to general and administrative. For the period from January 1, 2024 through February 13,
2024, Predecessor recorded an immaterial amount of stock-based compensation expense. For the three-month period ended September 30, 2024,
the Company recorded stock-based compensation expense of $0.4 million, of which $0.1 million was related to research and development
and $0.3 million was related to general and administrative.

For the nine-month period ended September 30,
2023, Predecessor recorded stock-based compensation expense of $0.08 million, of which $0.07 million was related to research and development
and $0.01 million was related to general and administrative. For the three-month period ended September 30, 2023, the Predecessor recorded
stock-based compensation expense of $0.02 million, of which $0.02 million was related to research and development and approximately $0
was related to general and administrative.

As of September 30, 2024, the Company had $1.5
million of unamortized stock-based compensation cost related to unvested stock options, which is expected to be recognized over a weighted
average period of 1.7 years. The weighted average grant date calculated fair value per share of the Company’s options granted during
the period from February 14, 2024, through September 30, 2024, was $102.00.

There were no Predecessor options granted in
the nine-month period ended September 30, 2023.

NOTE 11 – 401(k) RETIREMENT SAVINGS PLAN

The Company sponsors a 401(k) defined contribution
plan covering eligible employees who elect to participate. The Company is allowed to make discretionary profit sharing and 401(k) matching
contributions as defined in the plan and as approved by the Board of Directors. The Company’s contributions for the period from
February 14, 2024 through September 30, 2024, was $40,459 and Predecessor contributions during the period from January 1, 2024 through
February 13, 2024 was $8,657. The Company’s contributions for the three-months ended September 30, 2024 was $